IDEAYA BIOSCIENCES INC (IDYA) Stock News

USA - Nasdaq - NASDAQ:IDYA - US45166A1025 - Common Stock

33.87 USD

+0.31 (+0.92%)

Last: 12/12/2025, 12:07:58 PM

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

IDYA Latest News, Press Relases and Analysis

All

Press Releases

a day ago - By: IDEAYA Biosciences, Inc.

IDEAYA Biosciences Completes Targeted Full Enrollment in Randomized Pivotal Phase 2/3 Trial (OptimUM-02) of Darovasertib in Combination with Crizotinib in First-line HLA*A2-Negative Metastatic Uveal Melanoma

2 days ago - By: IDEAYA Biosciences, Inc.

IDEAYA Biosciences Announces IND Submission for IDE574, a Potential First-In-Class KAT6/7 Dual Inhibitor for Breast and Lung Cancers

11 days ago - By: IDEAYA Biosciences, Inc.

IDEAYA Biosciences Announces IND Clearance for IDE034, a Potential First-in-Class Bispecific B7H3/PTK7 TOP1 ADC Targeting Multiple Solid Tumor Types

14 days ago - By: IDEAYA Biosciences, Inc.

IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

18 days ago - By: IDEAYA Biosciences, Inc.

IDEAYA Biosciences to Participate in Upcoming December 2025 Investor Relations Events

3 months ago - By: Benzinga

Buying IDEAYA Might Be The Wrong IDYA Right Now

a month ago - By: IDEAYA Biosciences, Inc.

IDEAYA Biosciences Reports Third Quarter 2025 Financial Results and Provides Business Update

a month ago - By: IDEAYA Biosciences, Inc.

IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

2 months ago - By: IDEAYA Biosciences, Inc.

IDEAYA Biosciences to Participate in Upcoming November 2025 Investor Relations Events

2 months ago - By: Benzinga - Mentions: ZION ES MAR PL ...

SLB To Rally Around 44%? Here Are 10 Top Analyst Forecasts For Tuesday

2 months ago - By: IDEAYA Biosciences, Inc.

IDEAYA Biosciences Announces Positive Phase 2 Data for Darovasertib in the Neoadjuvant Setting of Primary Uveal Melanoma in a Proffered Paper Oral Presentation at ESMO 2025

2 months ago - By: IDEAYA Biosciences, Inc.

IDEAYA Biosciences Reports Positive Median Overall Survival Data from Phase 2 Trial of the Darovasertib and Crizotinib Combination in First-line Metastatic Uveal Melanoma at the 2025 Society for Melanoma Research Congress

3 months ago - By: IDEAYA Biosciences, Inc.

IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

3 months ago - By: IDEAYA Biosciences, Inc.

IDEAYA Biosciences Announces Positive Interim Phase 2 Data for Darovasertib in the Neoadjuvant Setting of Primary Uveal Melanoma

3 months ago - By: IDEAYA Biosciences, Inc.

IDEAYA Biosciences and Hengrui Pharma Present Positive Phase 1 Data for IDE849 (SHR-4849), a Potential First-in-Class DLL3 TOP1 ADC, in Small Cell Lung Cancer at the IASLC 2025 World Conference on Lung Cancer

3 months ago - By: IDEAYA Biosciences, Inc.

IDEAYA Biosciences Announces First-Patient-In for Phase 1/2 Combination Trial of IDE397, A Potential First-in-Class MAT2A Inhibitor, and Trodelvy® in MTAP-Deletion Non-Small Cell Lung Cancer

3 months ago - By: IDEAYA Biosciences, Inc.

IDEAYA Biosciences Announces IND Submission for IDE892, a Potential Best-In-Class PRMT5 Inhibitor for MTAP-Deletion Solid Tumors

3 months ago - By: IDEAYA Biosciences, Inc.

Servier and IDEAYA Biosciences Partner to Bring Darovasertib, a Promising Uveal Melanoma Treatment, to Patients Worldwide

3 months ago - By: IDEAYA Biosciences, Inc.

IDEAYA Biosciences to Present First Median Overall Survival Data from Phase 2 Trial of the Darovasertib / Crizotinib Combination in Metastatic Uveal Melanoma at the 2025 Society for Melanoma Research Congress

4 months ago - By: IDEAYA Biosciences, Inc.

IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

4 months ago - By: IDEAYA Biosciences, Inc.

IDEAYA Biosciences to Participate in Upcoming September 2025 Investor Relations Events

4 months ago - By: IDEAYA Biosciences, Inc.

IDEAYA Biosciences Announces Agenda for 10-Year Anniversary R&D Day on September 8, 2025

4 months ago - By: The Motley Fool

IDEAYA (IDYA) Q2 Net Loss Improves 27%

4 months ago - By: IDEAYA Biosciences, Inc.

IDEAYA Biosciences, Inc. Reports Second Quarter 2025 Financial Results and Provides Business Update

4 months ago - By: IDEAYA Biosciences, Inc.

IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

5 months ago - By: IDEAYA Biosciences, Inc.

IDEAYA Biosciences Announces Proffered Paper Oral Presentation at ESMO 2025 for Phase 2 Clinical Trial of Neoadjuvant Darovasertib in Primary Uveal Melanoma

5 months ago - By: IDEAYA Biosciences, Inc.

IDEAYA Biosciences Announces 10-Year Anniversary R&D Day on September 8, 2025 to Present Multiple Clinical Data Updates and Outline Future Growth Strategy

5 months ago - By: IDEAYA Biosciences, Inc.

IDEAYA Biosciences and Hengrui Pharmaceuticals Announce Oral Presentation at IASLC 2025 World Conference on Lung Cancer for IDE849 (SHR-4849), a Potential First-in-Class DLL3-TOP1 ADC

5 months ago - By: IDEAYA Biosciences, Inc.

IDEAYA Biosciences to Participate in Upcoming July 2025 Investor Relations Event

6 months ago - By: IDEAYA Biosciences, Inc.

IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)